Nautilus Biotechnolgy, Inc.
NAUTAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Sep 29, 2026 | Roth Capital | Max Masucci | $3.50(+215%) | $1.11 | TheFly |
| Feb 28, 2025 | Guggenheim | $2.50(+92%) | $1.30 | TheFly | |
| Jun 27, 2024 | Guggenheim | Subbu Nambi | $6.00(+163%) | $2.29 | StreetInsider |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Guggenheim | maintain | Buy | Feb 27, 2026 |
| Goldman Sachs | downgrade | Neutral →Sell | Dec 5, 2024 |
| Morgan Stanley | maintain | Equal Weight | Aug 3, 2023 |
| Goldman Sachs | maintain | Neutral | Aug 3, 2022 |
| Morgan Stanley | maintain | Equal Weight | Aug 3, 2022 |
| Goldman Sachs | maintain | Neutral | Jul 14, 2022 |
| Goldman Sachs | maintain | Neutral | Apr 13, 2022 |
| Morgan Stanley | maintain | Equal Weight | Jan 6, 2022 |
| Cowen & Co. | maintain | Outperform | Nov 2, 2021 |
| Goldman Sachs | maintain | Neutral | Aug 4, 2021 |
| Jefferies | maintain | Buy | Jul 13, 2021 |
Earnings History
Next report: Feb 25, 2027 · EPS est. $-0.15| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Oct 27, 2026 | $-0.12 | $-0.14 | $234.0K | $206.3K |
| Jul 28, 2026 | $-0.11 | $-0.14 | $190.0K | $100.0K |
| Apr 28, 2026 | $-0.12 | $-0.14 | — | $250.0K |
| Feb 26, 2026 | $-0.11 | $-0.14 | — | $1.3M |
| Oct 27, 2025 | $-0.11 | $-0.15 | — | — |
| Jul 31, 2025 | $-0.12 | $-0.15 | — | — |
| Apr 29, 2025 | $-0.13 | $-0.14 | — | — |
| Feb 26, 2025 | $-0.14 | $-0.16 | $9.6M | — |
News
New oncology assays reached tau-level precision in one year instead of five, suggesting the core technology scales faster than expected.
NAUT is extending Voyager from tau into oncology, which I think will give it more applications for its targeted proteoform platform. NAUT also has research collaborations and SEEDS participation. In my view, this corroborates that there's real scientific interest in their platform. Management's runway projection should be enough to reach their planned launch of Voyager instruments and initial assay kits.
Nautilus Biotechnology, Inc. (NAUT) Q3 2026 Earnings Call Transcript
Nautilus Biotechnology NASDAQ: NAUT reported third-quarter revenue of $200,000 as it continued its transition toward commercialization of its Voyager proteomics platform, with management reaffirming plans to begin taking platform pre-orders in early 2027 and start instrument shipments in mid-2027.
Nautilus expects to receive up to $6 million to bring its Voyager™ Platform to a multidisciplinary team integrating protein science, AI, and computational modeling to develop new diagnostics and therapeutics Nautilus expects to receive up to $6 million to bring its Voyager™ Platform to a multidisciplinary team integrating protein science, AI, and computational modeling to develop new diagnostics and therapeutics
SEATTLE, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2026.
SEATTLE, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter 2026 before market open on Tuesday, October 27, 2026.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT - Get Free Report) was the target of unusually large options trading on Monday. Stock traders bought 3,253 call options on the stock. This represents an increase of 1,427% compared to the average daily volume of 213 call options. Nautilus Biotechnology Stock Performance NAUT stock traded up $0.34 during midday trading
You can't buy Neuralink stock yet, but its supply chain is already public. Here are the brain-computer interface stocks to watch before the Neuralink IPO.
First large-scale, single-molecule analysis of the tau proteoform landscape reveals unique disease-associated modifications, a new source of potential biomarkers and drug targets, and a method Nautilus is now extending across disease areas First large-scale, single-molecule analysis of the tau proteoform landscape reveals unique disease-associated modifications, a new source of potential biomarkers and drug targets, and a method Nautilus is now extending across disease areas